This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Cameron DA, Camidge DR, Oyee J, Hirsch M.Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer. British Journal of Cancer 9912: 1984-1990, 16 Dec 2008
Rights and permissions
About this article
Cite this article
Fulvestrant: benefits at acceptable costs in advanced breast cancer. Pharmacoecon. Outcomes News 571, 1 (2009). https://doi.org/10.2165/00151234-200905710-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905710-00001